Introduction:
In the modern era, the use of surgically implanted left
ventricular assist devices (LVADs) as a bridge therapy to either recovery or
cardiac transplantation has given a hope at the end of the HF course of
disease. More recently, the use of LVADs as “DT” has further illuminated a
future for patients with end-stage HF.
Today, LVADs have evolved from large, bulky pulsatile systems
to smaller, compact, fully implantable continuous flow (CF) pumps. These
CF-LVADs use rotodynamic pumps to transfer kinetic energy from a circulating impeller
to the bloodstream, thereby generating forward flow .
Starling et al. summarized the rate of device thrombosis
among 837 patients across three implantation centers in USA, and Kirklin et al.
described data reported to the Interagency Registry for Mechanically Assisted
Circulatory Support (INTERMACS) on the rate of device thrombosis among 6910
patients from 2011 till April 2014. But all these big studies were done on
Heart Mate2 devices (Thoratec) and very few were done on (HeartWare) HVAD
devices.
Case Report:
39
years old man was diagnosed with severe dilated cardiomyopathy since 2003 with
recurrent admissions due to decompensated congestive heart failure. Dual
Chamber ICD was inserted in 2012, but removed after few months due to infection
and thrombosis. He is a known diabetic on insulin therapy, heavy smoker with
liver cardiac cirrhosis and has severe chronic kidney disease with baseline
creatinine around 200 mmol/L. Echocardiography showed severe LV dysfunction
with EF less than 20% and RV moderate to severe dysfunction with systolic PAP
pressure 55-65 mmHg.
No comments:
Post a Comment